By Fineline Cube Insilico Medicine (HKG: 3696) announced the nomination of ISM9077, an AI-powered, potential first-in-class Target Y inhibitor, as a preclinical candidate (PCC) for the treatment of ophthalmic diseases, including dry age-related macular degeneration (dry AMD), uveitis, and dry eye disease. This marks the company’s 32nd PCC nominated since 2021, highlighting the productivity of its proprietary AI-driven drug discovery platform.
Development Milestone | ISM9077
| Parameter | Detail |
|---|---|
| Candidate | ISM9077 (Target Y inhibitor) |
| Discovery Platform | Insilico’s proprietary AI platform |
| Classification | Potential first-in-class |
| PCC Number | 32nd since 2021 |
| Primary Indications | Dry AMD, uveitis, dry eye disease |
| Development Stage | Preclinical candidate (PCC) |
| Next Steps | IND-enabling studies |
Preclinical Profile & Mechanism of Action
- Potency: Demonstrated potent cross-species inhibitory activity against Target Y
- Pharmacokinetics: Shows superior target-tissue exposure and permeability, critical for ophthalmic applications
- Safety: Exhibits a favorable safety profile in preclinical models
- Mechanism: Effectively modulates inflammatory responses under pathological conditions through novel Target Y inhibition
- Therapeutic Expansion: The molecule’s innovative mechanism enables expansion beyond ophthalmology into broader inflammatory and aging-related conditions
Therapeutic Expansion Opportunities
ISM9077’s mechanism of action positions it for potential application across multiple therapeutic areas linked to chronic inflammation and aging biology:
- Neurodegenerative diseases
- Inflammatory bowel disease (IBD)
- Cardiovascular disease
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Obesity
This broad applicability reflects Insilico’s strategic focus on targeting fundamental aging processes that underlie multiple chronic diseases, potentially enabling a single molecule to address diverse unmet medical needs.
Strategic Implications
- AI Platform Validation: The nomination of ISM9077 as the 32nd PCC since 2021 demonstrates the continued productivity and validation of Insilico’s AI-driven discovery engine
- Ophthalmology Focus: Entry into ophthalmic diseases represents a strategic expansion into a high-value therapeutic area with significant unmet needs, particularly in aging populations
- Pipeline Diversification: The candidate’s potential across multiple inflammatory conditions provides optionality for future development prioritization based on clinical and commercial considerations
- First-in-Class Potential: As a potential first-in-class Target Y inhibitor, ISM9077 could command premium pricing and market exclusivity if successfully developed
Forward‑Looking Statements
This brief contains forward-looking statements regarding drug development, therapeutic potential, and business strategy. Actual results may differ materially due to risks including preclinical and clinical trial outcomes, regulatory approvals, competitive developments, and the inherent uncertainties of pharmaceutical development.-Fineline Info & Tech